Danaparoid—Consensus Recommendations on Its Clinical Use
2024

Danaparoid: Clinical Use Recommendations

publication Evidence: moderate

Author Information

Author(s): Bauersachs Rupert M., Lindhoff-Last Edelgard, Klamroth Robert, Koster Andreas, Schindewolf Marc, Magnani Harry

Primary Institution: Cardioangiology Center Bethanien, Frankfurt, Germany

Hypothesis

What are the optimal dosing regimens for danaparoid in various clinical situations?

Conclusion

The study provides detailed interdisciplinary dosing recommendations for the safe and effective use of danaparoid.

Supporting Evidence

  • Danaparoid has been used for over 40 years for DVT prophylaxis and treatment of HIT.
  • Current dosing recommendations are based on more than 40 years of clinical experience.
  • Interdisciplinary expert groups analyzed evidence to develop consensus on dosing regimens.

Takeaway

Danaparoid is a medicine used to prevent blood clots, and this study gives doctors advice on how to use it safely in different situations.

Methodology

The study summarizes evidence from clinical studies, case reports, and expert consensus to develop dosing recommendations.

Potential Biases

Potential biases may arise from the reliance on published studies and expert consensus.

Limitations

The recommendations are based on existing literature and expert opinion, which may not cover all clinical scenarios.

Digital Object Identifier (DOI)

10.3390/ph17121584

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication